REVIEW Fangchinoline, an bisbenyzylisoquinoline macrocyclic alkaloid derived from the dry roots of Stephaniae tetrandrine S. Moore (Menispermaceae), has been shown to possess cytotoxic, anti-inflammatory, anantioxidant properties and antiviral properties. Fangchinoline can inhibit breast cancer cell and reduced expression of cyclin D1, cyclin D3, and cyclin E, and increased expression of the cyclin-dependent kinase (CDK) inhibitors, p21/WAF1, and p27/KIP1. Moreover, fangchinoline also inhibited the kinase activities of CDK2, CDK4, and CDK6. These results suggest that Fangchinoline can inhibit human breast cancer cell proliferation and may have potential applications in cancer therapy. Fangcholine has also been shown to inhibit HIV1 replication replication by interfering with gp160 proteolytic processing.
Xing ZB, Yao L, Zhang GQ, Zhang XY, Zhang YX, Pang D. Fangchinoline inhibits breast adenocarcinoma proliferation by inducing apoptosis. Chem Pharm Bull (Tokyo). 2011;59(12):1476-80.
Wang N, Pan W, Zhu M, Zhang M, Hao X, Liang G, Feng Y. Fangchinoline induces autophagic cell death via p53/sestrin2/AMPK signalling in human hepatocellular carcinoma cells. Br J Pharmacol. 2011 Sep;164(2b):731-42.
Xing Z, Zhang Y, Zhang X, Yang Y, Ma Y, Pang D. Fangchinoline Induces G1 Arrest in Breast Cancer Cells Through Cell-Cycle Regulation. Phytother Res. 2013 Feb 11. doi: 10.1002/ptr.4936.
Fangchinoline induces G0/G1 arrest by modulating the expression of CDKN1A and CCND2 in K562 human chronic myelogenous leukemia cells. Wang Y, Chen J, Wang L, Huang Y, Leng Y, Wang G. Exp Ther Med. 2013 Apr;5(4):1105-1112.